FilippiMPreziosaPCopettiMGray matter damage predicts the accumulation of disability 13 years later in MS. Neurology2013; 81: 1759–1767.
2.
HorakovaDZivadinovRWeinstock-GuttmanBEnvironmental factors associated with disease progression after the first demyelinating event: Results from the multi-center SET study. PloS One2013; 8: e53996.
3.
MehtaVPeiWYangGIron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PloS One2013; 8: e57573.
4.
ChiaravallotiNDMooreNBNikelshpurOMAn RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial. Neurology2013; 81: 2066–2072.
5.
HortonLCongerACongerDEffect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology2013; 80: 1862–1866.
6.
TarakciEYeldanIHuseyinsinogluBEGroup exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: A randomized controlled trial. Clin Rehabil2013; 27: 813–822.
7.
GhezziAAnnovazziPCoccoEEndovascular treatment of CCSVI in patients with multiple sclerosis: Clinical outcome of 462 cases. Neurol Sci2013; 34: 1633–1637.
8.
DahlhausSHoepnerRChanADisease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry2013; 84: 1068–1074.
9.
RuetADeloireMHamelDCognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: A 7-year longitudinal study. J Neurol2013; 260: 776–784.
10.
SundstromPNystromLSvenningssonASick leave and professional assistance for multiple sclerosis individuals in Vasterbotten County, northern Sweden. Mult Scler2003; 9: 515–520.
11.
TinghogPHillertJKjeldgardLHigh prevalence of sickness absence and disability pension among multiple sclerosis patients: A nationwide population-based study. Mult Scler2013; 19: 1923–1930.
12.
MoorePHardingKEClarksonHDemographic and clinical factors associated with changes in employment in multiple sclerosis. Mult Scler2013; 19: 1647–1654.
13.
ShieldsSParkesL. Baseline responses of multiple sclerosis patients participating in the PROMS survey: Impact of disease-modifying therapies and support services on patient-reported outcomes. Association of British Neurologists. Glasgow. J Neurol Neurosurg Psychiatry2013; 84: e2.
14.
KrauseIKernSHorntrichAEmployment status in multiple sclerosis: Impact of disease-specific and non-disease-specific factors. Mult Scler2013; 19: 1792–1799.
15.
PalmerAJColmanSO’LearyBThe economic impact of multiple sclerosis in Australia in 2010. Mult Scler2013; 19: 1640–1646.
16.
WickstromANystromJSvenningssonA. Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment. Mult Scler2013; 19: 622–630.
17.
PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
18.
OlofssonSWickstromAHager GlenngardAEffect of treatment with natalizumab on ability to work in people with multiple sclerosis: Productivity gain based on direct measurement of work capacity before and after 1 year of treatment. BioDrugs2011; 25: 299–306.
